TRDA

4.3506.25%
NJ

Nathan J. Dowden

President & COO

Mr. Nathan J. Dowden also known as Nate, has been Chief Operating Officer of Entrada Therapeutics, Inc., since November 2019 and serves as its President since January 1, 2024 and served as its Secretary. He joined Entrada in November 2019. He served as a Senior Vice President of Strategy & Corporate Development at Rubius Therapeutics, Inc. until July 25, 2019. Mr. Dowden served as a Senior Vice President of Corporate Development at Rubius Therapeutics, Inc. since March 2016. Mr. Dowden has strategy, investment and operational experience in the healthcare field. Mr. Dowden served as a Managing Director in the Huron LifeScience consulting practice. He joined Huron in 2014 after helping to grow and lead and finally sell The Frankel Group after many years. He served as Managing Director and Managing Partner of The Frankel Group LLC (also known as The Frankel Group). Mr. Dowden has led a wide range of strategic, financial and scientifically oriented engagements. His efforts include work in various therapeutic groups including: oncology, diabetes rheumatology, critical care, infectious disease, dermatology, interventional cardiology, pulmonology, gastroenterology, degenerative neurology, pain management, hematology and orthopedics. Across those areas of medicine his technology platform experience includes stem cells & tissue engineering, immunotherapeutic & tolerance (e.g., antibodies, vaccines) proteins, peptides & constructs thereof, small molecules, drug delivery and genomics. Mr. Dowden's expertise includes forecasting & franchise strategy development, incubator & new business creation, product launch & market planning, business development & investment advisory, new product profile & clinical trial development. Mr. Dowden developed a pharmaceutical e-commerce spin-off investment for a diversified multi-billion dollar medical products company. He developed a manufacturing capacity assessment in preparation for the approval of a phase III biologic in infectious disease. He assisted in developing astrategy for a global biological products company and assessed the ten-year trends in U.S. Healthcare for an ex-U.S. pharmaceutical client. Mr. Dowden constructed strategic launch & marketing plans in endocrinology, hematology, interventional cardiology, gastroenterology and rheumatology. Mr. Dowden served as a Consultant of Ernst & Young LLP, where his engagement experience included Payor (Mergers & Acquisition, Operational Assessment, IT systems) and Provider (Mergers & Acquisition, Operational Assessment). He worked in Searle Pharmaceutical, where he managed Care Strategy - Evaluation of strategic alliance efforts and Service product assessment and recommendations. Mr. Dowden also served as a Financial Analyst of CIGNA Healthcare. He holds an MBA in Finance & Marketing, GSB from The University of Chicago - Booth School of Business from 1994 to 1996 and B.S. in Finance from The University of Connecticut from 1987 to 1991.

Positions